Results 91 to 100 of about 29,612 (275)
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
Diabetes, Obesity and Metabolism, EarlyView.Abstract The development of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors represents a major turning point in the effort to preserve kidney function and prevent cardiovascular events and heart failure hospitalisations in those at high risk. These agents have now transcended their original glucose‐lowering indication and provide a range of clinical
Daniel Vincent O'Hara, Meg J. Jardine
wiley +1 more source
An emerging protagonist: Sodium Glucose Co-transporters (SGLTs) as a burgeoning target for the treatment of diabetes mellitus [PDF]
, 2012 Contemporary therapies to rationalize the hyperglycaemia in type 2 diabetes mellitus (T2DM) generally involve insulin-dependent mechanisms and lose their effectiveness as pancreatic b-cell function decreases to a greater extent. The kidney emerges out as
Danish Ahmed +3 more
core +2 more sources
Diabetes, Obesity and Metabolism, EarlyView.Abstract Background Sodium‐glucose cotransporter (SGLT) 2 inhibitors attenuate fasting glomerular hyperfiltration in people with type 2 diabetes (T2D). However, SGLT2‐inhibition increases glucagon levels, which facilitate postprandial hyperfiltration.
Michaël J. B. van Baar +10 more
wiley +1 more source
Targeting acute hyperglycaemia in clinical practice [PDF]
, 2007 The UKPDS established the benefit of tight glycaemic control in preventing microvascular disease but was unable to demonstrate an effect on cardiovascular disease.
Heller, S.
core +1 more source
Importance of screening for glycosuria and proteinuria in antenatal care
Gomal Journal of Medical Sciences, 2004 Background: The identification and treatment of women with gestational diabetes mellitus continues to be controversial due to the costs involved in the screening and treatment, even in developed countries.
Aziz Marjan Khattak +5 more
doaj
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease. [PDF]
PLoS ONE, 2016 Pharmacological inhibition of the proximal tubular sodium-glucose linked cotransporter-2 (SGLT2) leads to glycosuria in both diabetic and non-diabetic settings.
Yanling Zhang +3 more
doaj +1 more source
Renal Glycosuria without Hyperglycemia in Cyclosporine-Treated Rats
Kidney Research and Clinical Practice, 2012 The pathogenesis of post-transplant diabetes mellitus is thought to be partly related to the direct toxic effect of cyclosporine on pancreatic β-cells and the resultant decrease in insulin synthesis and secretion.
Chang Hwa Lee +3 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims We assessed the effects of dapagliflozin on natriuresis and blood pressure in patients with type 2 diabetes and chronic kidney disease (CKD) and evaluated the consistency of these effects across patients with type 2 diabetes without CKD and CKD without type 2 diabetes.
Jelle M. Beernink +16 more
wiley +1 more source
Symposium 17: Beta cell response to inflammation
Revista de la Sociedad Argentina de Diabetes, 2020 Symposium 17: Beta cell failure Beta cell response to inflammation The current dogma understands the pathogenesis of diabetes, especially type 2, as the resistance to insulin that causes the exhaustion of the beta-cell, which will later cause ...
Marcelo Perone
doaj +1 more source
Ifosfamide-induced nephrogenic diabetes insipidus and Fanconi syndrome in a patient with femur osteosarcoma. [PDF]
Caspian J Intern MedBackground: Ifosfamide-induced Fanconi syndrome is a relatively infrequent complication that generally occurs in young patients with a high cumulative dose of ifosfamide; and is commonly characterized by glycosuria, proteinuria, electrolyte abnormalities,
Concepción-Zavaleta M +8 more
europepmc +2 more sources